Deutsche medizinische Wochenschrift
-
Dtsch. Med. Wochenschr. · Sep 2024
Comparative Study[Comparison of LDL cholesterol serum concentrations in patients after acute coronary syndrome between 2018 and 2022 in Germany and Europe].
ESC/EAS guidelines for the management of dyslipidemia after acute coronary syndrome (ACS) were updated in 2019 with lower LDL cholesterol (LDL-C) goals. Their effect on LDL-C lowering in Germany and across Europe is not known. The EuroPath IV survey was designed to compare the lipid management in patients post ACS in the year 2022 with 2018. ⋯ Achievement of LDL-C goals improved after the update of the ESC/EAS lipid guidelines in 2019 but LDL-C goal achievement remains still very low. Even less patients in Germany achieved the LDL-C goals compared to other European countries.
-
Dtsch. Med. Wochenschr. · Sep 2024
[Importance and prevalence of multidrug-resistant gram-negative bacteria in Germany].
Infections with multidrug-resistant gram-negative bacterial species are a great concern in clinics in Germany. By limiting therapeutic options dramatically, these bacteria pose a significant threat to patient health and cause extensive pressure on hygiene systems and patient management. ⋯ According to established surveillance systems like national reporting systems, KISS or the National Reference Centre, multidrug-resistant bacteria are constantly on the rise in Germany. Although several novel therapeutic options have been approved recently, these bacteria represent a constant challenge and it may be necessary to discuss if the present hygiene recommendations need an update for an efficient and targeted prevention of transmission.
-
Dtsch. Med. Wochenschr. · Sep 2024
Review[Small intestinal bacterial overgrowth (SIBO) - Therapy, nutrition, microbiome].
SIBO (small intestinal bacterial overgrowth) is defined by bacterial overgrowth or colonization of the small intestine in combination with gastrointestinal symptoms such as bloating, nausea, pain, diarrhoea, malabsorption and food intolerance. SIBO can be caused by various mechanisms such as reduced intestinal motility, altered gastrointestinal anatomy, reduced gastric acid or pancreatic enzyme production, altered bile acid metabolism, or immune defects. Accordingly, SIBO often develops secondary to different underlying diseases. ⋯ However, both aspects have so far been insufficiently investigated. Nevertheless, elemental diets, carbohydrate-reduced diets, as well as pre- and probiotics are potential therapy options. This article provides a summary of current knowledge on the pathophysiology, diagnosis and treatment of SIBO, with particular emphasis on the role of nutrition and the microbiome.